赛伦生物(688163) - 2022 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2022 was CNY 174,221,005.91, a decrease of 16.52% compared to CNY 208,693,627.46 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 64,135,803.84, down 16.14% from CNY 76,482,795.73 in the previous year[20]. - The net profit after deducting non-recurring gains and losses decreased by 35.71% to CNY 44,693,930.62 from CNY 69,513,945.85 in 2021[21]. - The net cash flow from operating activities fell by 26.41% to CNY 67,913,773.25 compared to CNY 92,288,488.20 in 2021[21]. - The company's total assets increased by 188.68% to CNY 1,163,066,774.97 at the end of 2022, up from CNY 402,891,055.95 at the end of 2021[21]. - The net assets attributable to shareholders grew by 203.36% to CNY 1,121,290,451.58 at the end of 2022, compared to CNY 369,629,071.96 at the end of 2021[21]. - Basic earnings per share decreased by 32.98% to CNY 0.63 in 2022 from CNY 0.94 in 2021[22]. - The company's revenue from the biopharmaceutical sector was approximately 174.22 million, with a gross margin of 83.77%, reflecting a slight increase of 0.18 percentage points compared to the previous year[112]. Dividend Distribution - The proposed profit distribution plan for 2022 is to distribute a cash dividend of RMB 7.50 per 10 shares (including tax), totaling RMB 81,165,000, which accounts for 126.55% of the net profit attributable to shareholders in 2022[5]. - In 2021, the company distributed cash dividends of RMB 97,398,000, which accounted for 127.35% of the net profit attributable to shareholders[190]. - The company has a well-defined decision-making process for dividend distribution, ensuring transparency and protection of minority shareholders' rights[191]. Research and Development - The R&D expenditure as a percentage of operating revenue was 8.87%, down 3.47 percentage points from 12.34% in 2021[22]. - The company has invested a total of ¥15,457,131.29 in R&D for the year, a decrease of 40% compared to ¥25,763,088.98 in the previous year[75]. - The company has applied for 6 new invention patents during the reporting period[33]. - The company is currently conducting clinical trials for the anti-viper venom serum, with a total investment of ¥1,600,000 and ¥1,065,400 invested to date[77]. - The company has developed proprietary technologies for toxin protein research, enabling effective analysis and purification of toxic components for the development of antitoxin drugs[65]. - The company is engaged in ongoing research and development of new technologies to enhance the quality of antivenoms and antitoxins, ensuring affordability and high production capacity[63]. Market Position and Strategy - The company is the only domestic producer and seller of snake antivenom, fulfilling emergency clinical needs in the public health sector[37]. - The company has a comprehensive competitive advantage in the field of antivenom and antitoxin drugs, supported by a rich R&D and technical team, GMP-certified production facilities, and a nationwide medical promotion team[36]. - The biopharmaceutical market in China is projected to reach RMB 1,319.8 billion by 2030, with a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030[48]. - The company aims to enhance product promotion and coverage to reduce fatalities and disabilities caused by snakebites in China[53]. - The company is positioned to leverage its unique market position and advanced technology to expand its product offerings and market share[52]. Risk Management - The company has detailed various risks faced during operations in the report, emphasizing the importance of risk management[4]. - The report includes a forward-looking statement risk disclaimer, cautioning investors about potential uncertainties in future plans[6]. - The company faces risks related to price control or competition that could lead to a decrease in product prices and impact revenue growth[91]. - The company has a risk of product safety due to potential pathogens remaining in the plasma used for production, despite implementing screening and virus inactivation measures[90]. Corporate Governance - The company has established a standardized corporate governance structure in compliance with relevant laws and regulations, holding one shareholders' meeting and six board meetings during the reporting period[157]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors and stakeholders[158]. - The company maintains independence from its controlling shareholder, ensuring no non-operational use of company funds[157]. - The company has established a comprehensive internal control system to ensure effective governance and risk management, covering various aspects including financial management and major investments[197]. Employee Management - The company emphasizes employee training, implementing various training programs to enhance skills and professional knowledge[187]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 5.6352 million RMB[174]. - The company has a competitive and equitable salary policy, aiming to motivate employees and enhance their performance[186]. - The number of R&D personnel has increased to 41, accounting for 13.31% of the total workforce, compared to 40 personnel and 13.56% in the previous year[80].